Lincomycin Hydrochloride Injection shortage
To Be Discontinued 3 presentations · 2 manufacturers · first FDA posting 2026-02-25 · last update 2026-03-26
Manufacturers: Pfizer Inc., XGen Pharmaceuticals DJB, Inc.
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Lincocin, Injection, 2 mL multiple dose vial (NDC 0009-0104-04) | Pfizer Inc. | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 02/25/2026 Updated 02/25/2026 Discontinued 02/25/2026 |
| Lincomycin Hydrochloride, Injection, 600 mg/2 mL vial x 10 count (NDC 39822-0350-2) | XGen Pharmaceuticals DJB, Inc. | To Be Discontinued | — | A business decision was made to discontinue manufacture of the drug. | Posted 03/26/2026 Updated 03/26/2026 Discontinued 03/26/2026 |
| Lincomycin Hydrochloride, Injection, 3 grams/10 mL vial x 10 count (NDC 39822-0355-6) | XGen Pharmaceuticals DJB, Inc. | To Be Discontinued | — | A business decision was made to discontinue manufacture of the drug. | Posted 03/26/2026 Updated 03/26/2026 Discontinued 03/26/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)